financetom
Business
financetom
/
Business
/
Alphabet's Google Antitrust Case Result 'Best-Case Outcome,' Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alphabet's Google Antitrust Case Result 'Best-Case Outcome,' Oppenheimer Says
Sep 3, 2025 8:24 AM

11:12 AM EDT, 09/03/2025 (MT Newswires) -- Alphabet's (GOOG, GOOGL) legal "win" in the antitrust case ruling on Google's ( GOOG ) monopoly is the "best-case outcome" and removes the medium-term overhang on valuation and sentiment, Oppenheimer said in a Tuesday note.

According to the recent court ruling by US District Judge Amit Mehta for the District of Columbia, Google ( GOOG ) is not required to divest its Chrome browser. The tech giant can continue to pay Apple ( AAPL ) for users of Google Search despite being barred from exclusive contracts, Oppenheimer analysts said. Apple ( AAPL ) can renegotiate a deal for Search every year as the AI landscape evolves, they said.

Oppenheimer's April 2024 survey showed that 75% of iPhone users would choose Google Search as their search engine, with suggests that the impact of losing Apple ( AAPL ) exclusivity would likely be offset by lower traffic acquisition cost percentage to Apple ( AAPL ), the analysts said.

Among the notable aspects of the ruling are that Google ( GOOG ) is required to share search index data with qualified competitors but not advertising data, the analysts said. Google ( GOOG ) will also have to publicly disclose ad auction changes, but does not have to share query-level data with advertisers or offer publishers more options in how Search uses their content. Further, Google ( GOOG ) does not have to divest its Android operating system, and Google ( GOOG ) apps can remain as defaults within Android, the analysts noted.

Oppenheimer reiterated the tech giant's stock rating at outperform and increased the price target to $270 from $235.

Price: 229.87, Change: +17.88, Percent Change: +8.43

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Accenture to Form JV With Shipbuilding Group Fincantieri
Accenture to Form JV With Shipbuilding Group Fincantieri
Apr 10, 2025
06:12 AM EDT, 04/10/2025 (MT Newswires) -- Accenture ( ACN ) has agreed to form a 30/70 joint venture with Fincantieri Group unit Fincantieri NexTech to accelerate digital transformation in the cruise, defense, and port infrastructure sectors, the companies said Thursday. The Fincantieri Ingenium joint venture will initially focus on developing the Navis Sapiens system for new ships and to...
Factbox-Intel CEO Lip-Bu Tan's wide-ranging investments in China
Factbox-Intel CEO Lip-Bu Tan's wide-ranging investments in China
Apr 10, 2025
BEIJING/SAN FRANCISCO (Reuters) - Intel ( INTC ) CEO Lip-Bu Tan has made hundreds of investments in Chinese companies over decades through Walden International, the San Francisco venture capital firm he founded in 1987, and two Hong Kong-based holding companies, Sakarya Limited and Seine Limited. The following are some key investments uncovered by Reuters and their connections to Chinese state...
Keros Therapeutics adopts 'poison pill' plan
Keros Therapeutics adopts 'poison pill' plan
Apr 10, 2025
April 10 (Reuters) - Keros Therapeutics ( KROS ) said on Thursday its board had authorized a stockholder rights plan, also known as a poison pill, in response to rapid accumulations of the company's stock by some investors. The company also said it had launched a process to evaluate strategic alternatives, including a possible sale of the company. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved